Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J enters dermal filler market

This article was originally published in The Gray Sheet

Executive Summary

OrthoNeutrogena, a division of Ortho-McNeil-Janssen Pharmaceuticals which is part of Johnson & Johnson, enters the U.S. aesthetic facial dermal filler market with the June 27 PMA approval of its Evolence porcine collagen-based filler for correction of moderate to deep facial wrinkles and folds. The market roll-out will be conducted "throughout the second half of 2008" in coordination with physician training, the company says. Evolence has been available outside the U.S. since 2004. The product, which "does not require a pre-test" on prospective recipients, is "clinically proven to last through six months," J&J says. The firm plans to file additional data for 12-month duration approval. Competitors include Medicis (Restylane and Perlane), Allergan (Juvederm), BioForm (Radiesse), Artes Medical (ArteFill), Mentor (Prevelle Silk), and Anika (Elevess).Medicis (Restylane
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel